



Sabine Schmid

Kontakt

Sabine Schmid
Switzerland

sabine.schmid@kssg.ch

Bereiche

Medizinische Onkologie und Hämatologie

Publikationen (33)

UI Haq S, Schmid S, Aparnathi M, Hueniken K, Zhan L, Sacdalan D, Li J, Meti N, Patel D, Cheng D, Philip V, Tsao M, Cabanero M, de Carvalho D, Liu G, Bratman S, Lok B. Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction. *iScience* 2022; 25:105487.

Koster K, Appenzeller C, Lauber A, Früh M, Schmid S. Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. *Case Rep Oncol* 2022; 15:720-725.

Ramon-Patino J, Schmid S, Lau S, Seymour L, Gaudreau P, Li J, Bradbury P, Calvo E. iRECIST and atypical patterns of response to immuno-oncology drugs. *J Immunother Cancer* 2022; 10

Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind F, Ellinger J, Brossart P, Diem S, Schmid S, Jörgler M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. *J Immunother Cancer* 2022; 10

Schmid S, Jiang M, Brown M, Fares A, Garcia M, Soriano J, Dong M, Thomas S, Kohno T, Leal L, Diao N, Xie J, Wang Z, Zaridze D, Holcatova I, Lissowska J, Świątkowska B, Mates D, Savic M, Wenzlaff A, Harris C, Caporaso N, Ma H, Fernandez-Tardon G, Barnett M, Goodman G, Davies M, Pérez-Ríos M, Taylor F, Duell E, Schoettker B, Brenner H, Andrew A, Cox A, Ruano-Ravina A, Field J, Marchand L, Wang Y, Chen C, Tardon A, Shete S, Schabath M, Shen H, Landi M, Ryan B, Schwartz A, Qi L, Sakoda L, Brennan P, Yang P, Zhang J, Christiani D, Reis R, Shiraishi K, Hung R, Xu W, Liu G. Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. *Cancer Epidemiol Biomarkers Prev* 2022; 31:679-687.

Schmid S, Zhan L, Dietrich K, Khan K, Chowdhury M, Hermann M, Patel D, Zaeimi F, Leighl N, Sacher A, Feld R, Shepherd F, Donahoe L, de Perrot M, Cho B, Liu G, Bradbury P. Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. *Clin Lung Cancer* 2021; 23:e43-e53.

Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. *Lung Cancer* 2021; 156:91-99.

Schmid S, De Giorgi U, Hansen A, Beer T, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürcher-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Bianchini D, Chi K, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen M, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. *JAMA Netw Open* 2020; 3:e2021692.

Schmid S, Jochum W, Addeo A, Demmer I, Schär S, Janthur W, Wannesson L, König D, Britschgi C, Frösch P, Bouchaab H, Rothschild S, Blum V, Friedlaender A, Mauti L, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. *Cancer Immunol Immunother* 2020; 69:1605-1613.

Schmid S, Früh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?. *Lancet Oncol* 2020; 21:320-322.

Schmid S, Suipyte J, Herrmann C, Mousavi M, Hitz F, Früh M. Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. *Eur J Cancer Care (Engl)* 2020; 29:e13206.

<p>Schmid S, Omlin A. Progress in therapy across the spectrum of advanced prostate cancer. <i>Nat Rev Urol</i> 2019</p>
<p>Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. <i>BMC cancer</i> 2019; 19:902.</p>
<p>Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>Eur Urol Oncol</i> 2019</p>
<p>Betschart P, Schmid H, Klingbiel D, Engeler D, Gillessen Sommer S, Schwab C, Abt D, Rothermundt C, Schmid S, Babst C, Omlin A. Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. <i>Oncol Res Treat</i> 2019; 42:366-374.</p>
<p>Schmid S, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. <i>Lung Cancer</i> 2019</p>
<p>Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. <i>Lung Cancer</i> 2019; 130:149-155.</p>
<p>Mousavi S, Schmid S, Cerny T, Früh M. Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys. <i>Swiss Med Wkly</i> 2018; 148:w14708.</p>
<p>Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. <i>Cancer Manag Res</i> 2018; 10:5537-5544.</p>
<p>Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). <i>Cancer Immunol Immunother</i> 2018</p>
<p>Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrusch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. <i>J Thorac Oncol</i> 2018</p>
<p>Schmid S, Früh M. Immune checkpoint inhibitors and small cell lung cancer: what's new?. <i>J Thorac Dis</i> 2018; 10:S1503-S1508.</p>
<p>Isensee G, Péporté A, Müller J, Schmid S, Gillessen Sommer S, Omlin A. Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?. <i>Clin Genitourin Cancer</i> 2018; 16:349-354.</p>
<p>Schmid S, Früh M. Immune checkpoint inhibitors and small cell lung cancer: what's new?. <i>Journal of thoracic disease</i> 2018; 10:1503-1508.</p>

Glatzer M, Schmid S, Radovic M, Früh M, Putora P. The role of radiation therapy in the management of small cell lung cancer. *Breathe (Sheff)* 2017; 13:e87-e94.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung Cancer* 2017; 111:176-181.

Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. *ESMO Open* 2017; 2:e000172.

Schmid S, Diebold J, Jochum W, Reichegger H, Klingbiel D, Froesch P, Mark M, Rothschild S, Gautschi O, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). *J Thorac Oncol* 2016

Schmid S, Omlin A, Blum D, Strasser F, Gillessen Sommer S, Rothermundt C. Assessment of Anticancer-Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer - Going beyond PSA and Imaging, a Systematic Literature Review. *Ann Oncol* 2015

Schmid S, Rothermundt C, Weber J, van Leyen K, Sulz M, Stöckli S, Krull I, Krek W, Kloos P, Heinimann K, Hader C, Greiner J, Engeler D, Brändle M, Binet F, Gillessen Sommer S, Hundsberger T. Management of von Hippel-Lindau Disease: An Interdisciplinary Review. *Oncol Res Treat* 2014; 37:761-771.

Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp N, Gillessen Sommer S. Abiraterone--what is wrong with the adrenal glands?. *Clin Genitourin Cancer* 2014; 12:e133-7.

Dusemund F, Schneider T, Zeisel C, Rothermundt C, Kluckert T, Schmid S, Brutsche M. Endobronchial ultrasound-guided transbronchial needle aspiration of an intravascular sarcoma metastasis. *Respiration* 2013; 86:430-432.

Schmid S, Öhlschlegel C, Nagel W, Zeisel C, Müller J, Rothermundt C. Pulmonary embolism in a patient with primary renal synovial sarcoma: the important differential diagnosis of tumor embolism and its therapeutic implications. *Case Rep Oncol* 2013; 6:331-8.

Projekte (6)

Studie der Phase 2 zur Beurteilung der Wirksamkeit und Sicherheit von Pembrolizumab plus Prüfpräparate in Kombination mit Etoposid und Cisplatin oder Carboplatin als Erstlinientherapie bei Teilnehmenden mit kleinzelligem Lungenkrebs im fortgeschrittenen Stadium (MK-3475- B99)

Klinische Forschung - 29.09.2021 - 28.10.2028

Laufend

MK-3475-495 KeyImPaCT

Klinische Forschung - 12.12.2018 - 19.12.2020

Automatisch geschlossen

Randomisierte, offene, multizentrische Phase-2/3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Rogaratinib (BAY 1163877) im Vergleich zu Chemotherapie bei Patienten mit FGFR-positivem, lokal fortgeschrittenem oder metastatischem Urothelkarzinom, die vorher eine platinhaltige Chemotherapie erhalten haben

Klinische Forschung - 30.05.2018 - 31.12.2030

Laufend

Eribulin as 1st line treatment in elderly patients (≥ 70 years) with advanced breast cancer: a multicenter phase II trial

Klinische Forschung - 11.08.2015 - 30.06.2019

Automatisch geschlossen

An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors

Klinische Forschung - 08.07.2015 - 31.07.2019

Automatisch geschlossen

Impact of the addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients progressing on abiraterone treatment (MetAb-Pro): A phase II pilot study

Klinische Forschung - 24.10.2013 - 31.12.2014

Automatisch geschlossen